Tag #Weight-Loss Drugs

Showing 1 to 12 of 20 results

telegraaf.nl

🌐 75% Global Worthiness

Jun 6, 19:11

UK: Pregnancy Risk Linked to Weight-Loss Drugs and Birth Control Pills

In the UK, 40 women became pregnant while taking birth control pills and weight-loss drugs (Mounjaro, Saxenda, Ozempic/Wegovy); the MHRA warns of a potential link, advising against relying solely on oral contraceptives when using these drugs.

UK: Pregnancy Risk Linked to Weight-Loss Drugs and Birth Control Pills

In the UK, 40 women became pregnant while taking birth control pills and weight-loss drugs (Mounjaro, Saxenda, Ozempic/Wegovy); the MHRA warns of a potential link, advising against relying solely on oral contraceptives when using these drugs.

Progress

64% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the underlying mechanisms by which these weight-loss medications may reduce the effectiveness of oral contraceptives?

The weight-loss drugs Mounjaro, liraglutide (Saxenda), and semaglutide (Ozempic and Wegovy) may interfere with oral contraceptive effectiveness by slowing digestion and thus pill absorption. Of the 40 reported cases in the UK, 26 involved Mounjaro, nine liraglutide, and five semaglutide. The MHRA advises against solely relying on oral contraceptives when using these drugs, recommending condom use, especially for overweight women.

theguardian.com

🌐 75% Global Worthiness

Jun 5, 10:14

MHRA Warns of Pregnancy Risk with Weight-Loss Drugs

The UK's MHRA issued a warning about 40 reported pregnancies in women using weight-loss drugs like Ozempic, Wegovy, and Mounjaro, advising them to use effective contraception due to potential interactions and lack of safety data during pregnancy.

MHRA Warns of Pregnancy Risk with Weight-Loss Drugs

The UK's MHRA issued a warning about 40 reported pregnancies in women using weight-loss drugs like Ozempic, Wegovy, and Mounjaro, advising them to use effective contraception due to potential interactions and lack of safety data during pregnancy.

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the potential mechanisms by which weight-loss drugs may affect contraceptive effectiveness, and what types of contraception are recommended?

The MHRA's warning highlights a potential interaction between weight-loss drugs and oral contraceptives, particularly Mounjaro, which may reduce their effectiveness in overweight individuals. The increase in pregnancies reported among users suggests a need for clearer communication about contraception alongside these medications. The agency also notes that obesity itself can impact fertility, potentially increasing the chance of pregnancy.

bbc.com

🌐 85% Global Worthiness

May 16, 22:08

Novo Nordisk CEO Ousted Amidst Market Challenges and Share Price Drop

Novo Nordisk abruptly ousted its CEO, Lars Fruergaard Jørgensen, due to market challenges and a significant share price decline, despite a recent increase in sales, raising concerns about the company's future in the weight-loss drug market.

Novo Nordisk CEO Ousted Amidst Market Challenges and Share Price Drop

Novo Nordisk abruptly ousted its CEO, Lars Fruergaard Jørgensen, due to market challenges and a significant share price decline, despite a recent increase in sales, raising concerns about the company's future in the weight-loss drug market.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate consequences of Novo Nordisk's CEO ouster for the company's market position and investor confidence?

Novo Nordisk, the maker of Wegovy and Ozempic, abruptly removed its CEO, Lars Fruergaard Jørgensen, due to market challenges and a significant drop in share price over the past year. The company's market value has halved, and competitors like Eli Lilly are gaining ground. Jørgensen's departure will occur once a successor is found.

theglobeandmail.com

🌐 85% Global Worthiness

May 1, 16:13

WHO to Officially Endorse Weight-Loss Drugs for Obesity Treatment

The World Health Organization will officially endorse weight-loss drugs like Wegovy and Mounjaro for adult obesity treatment in August, addressing the over 1 billion people affected globally, with 70% in low- and middle-income countries, while acknowledging high costs and advocating for increased ac...

WHO to Officially Endorse Weight-Loss Drugs for Obesity Treatment

The World Health Organization will officially endorse weight-loss drugs like Wegovy and Mounjaro for adult obesity treatment in August, addressing the over 1 billion people affected globally, with 70% in low- and middle-income countries, while acknowledging high costs and advocating for increased ac...

Progress

32% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the WHO's decision regarding weight-loss drugs for obesity treatment, and what are its immediate implications for global health?

The World Health Organization (WHO) will officially endorse weight-loss drugs like Wegovy and Mounjaro to treat adult obesity, marking a significant shift in its approach to this global health issue. This decision follows clinical trials showing 15-20% weight loss and considers the over 1 billion people globally affected by obesity, with 70% residing in low- and middle-income countries.

theglobeandmail.com

🌐 75% Global Worthiness

Feb 6, 19:08

Eli Lilly Exceeds Profit Forecasts Despite Sales Disappointments

Eli Lilly, exceeding analysts' expectations, forecasts higher-than-expected annual profit despite recent sales misses for its Mounjaro and Zepbound drugs; the company's stock rose 1 percent in premarket trading.

Eli Lilly Exceeds Profit Forecasts Despite Sales Disappointments

Eli Lilly, exceeding analysts' expectations, forecasts higher-than-expected annual profit despite recent sales misses for its Mounjaro and Zepbound drugs; the company's stock rose 1 percent in premarket trading.

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the key risks and uncertainties that could affect Eli Lilly's ability to achieve its ambitious sales targets for 2025?

Eli Lilly's focus on expanding Mounjaro into new markets, coupled with its marketing strategy for Zepbound, suggests a proactive approach to market share competition with Novo Nordisk. The success of these strategies will be crucial in determining Lilly's ability to maintain its leading position in the growing weight-loss market.

bbc.com

🌐 85% Global Worthiness

Jan 28, 10:06

Kennedy-Oz Clash on Weight-Loss Drug Coverage Looms

The conflicting views of Robert F. Kennedy Jr. and Mehmet Oz on the Trump administration's policy regarding Medicare and Medicaid coverage of costly new weight-loss drugs create uncertainty, impacting millions' access to potentially life-changing medication.

Kennedy-Oz Clash on Weight-Loss Drug Coverage Looms

The conflicting views of Robert F. Kennedy Jr. and Mehmet Oz on the Trump administration's policy regarding Medicare and Medicaid coverage of costly new weight-loss drugs create uncertainty, impacting millions' access to potentially life-changing medication.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate impacts of the high cost and limited insurance coverage of new weight-loss drugs on patients' access to treatment and overall health outcomes?

The high cost of new weight-loss drugs, averaging \$1,000 per month, and limited insurance coverage create significant access barriers for many patients. Dr. Mollie Cecil's experience exemplifies this, highlighting how loss of coverage led to weight regain. This impacts patient health and raises concerns about equitable access to potentially life-changing medication.

dailymail.co.uk

🌐 85% Global Worthiness

Jun 5, 19:14

Ozempic Linked to Doubled Risk of Blinding Eye Condition

An Israeli study of 139,000 type 2 diabetes patients found those using Ozempic or similar weight-loss drugs were twice as likely to develop the blinding eye condition neovascular age-related macular degeneration (nAMD) compared to a control group, prompting further research into the drugs' potential...

Ozempic Linked to Doubled Risk of Blinding Eye Condition

An Israeli study of 139,000 type 2 diabetes patients found those using Ozempic or similar weight-loss drugs were twice as likely to develop the blinding eye condition neovascular age-related macular degeneration (nAMD) compared to a control group, prompting further research into the drugs' potential...

Progress

60% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does the study's methodology and findings contribute to our understanding of the potential causal link between GLP-1 receptor agonists and nAMD?

The study, published in JAMA Opthalmology, analyzed 139,000 type 2 diabetes patients, with roughly 46,000 using Ozempic or similar drugs. Over three years, the Ozempic group experienced 93 nAMD cases (0.2 percent), versus 88 cases (0.1 percent) in the control group. The increased risk is possibly linked to GLP-1 receptors in the eye, triggering blood vessel growth.

dailymail.co.uk

🌐 85% Global Worthiness

Jun 2, 01:12

Weight-Loss Drugs Linked to Increased Osteoporosis Risk

Weight-loss drugs such as Ozempic, Wegovy, and Mounjaro may cause significant bone and muscle loss, increasing osteoporosis risk, according to the Royal Osteoporosis Society. Up to 40 percent of weight loss from these drugs may come from bone and muscle, impacting approximately half a million users ...

Weight-Loss Drugs Linked to Increased Osteoporosis Risk

Weight-loss drugs such as Ozempic, Wegovy, and Mounjaro may cause significant bone and muscle loss, increasing osteoporosis risk, according to the Royal Osteoporosis Society. Up to 40 percent of weight loss from these drugs may come from bone and muscle, impacting approximately half a million users ...

Progress

56% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate health risks associated with the use of GLP-1 agonists for weight loss, and how significant is this issue given the number of users?

New research indicates that GLP-1 agonists, such as Ozempic, Wegovy, and Mounjaro, can cause significant muscle and bone loss in up to 40 percent of users, increasing the risk of osteoporosis and fractures. Half a million UK residents currently use these drugs, highlighting a substantial public health concern. This bone and muscle loss can impair strength, joint stability, and overall health.

tr.euronews.com

🌐 85% Global Worthiness

May 13, 01:12

GLP-1 Weight-Loss Drugs May Reduce Obesity-Related Cancer Risk by 41%

A study of nearly 6,400 obese and diabetic individuals found that GLP-1 receptor agonists, while less effective for weight loss than bariatric surgery, may reduce obesity-related cancer risk by 41%, potentially through inflammation reduction; however, this observational study requires further invest...

GLP-1 Weight-Loss Drugs May Reduce Obesity-Related Cancer Risk by 41%

A study of nearly 6,400 obese and diabetic individuals found that GLP-1 receptor agonists, while less effective for weight loss than bariatric surgery, may reduce obesity-related cancer risk by 41%, potentially through inflammation reduction; however, this observational study requires further invest...

Progress

20% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of the findings on cancer prevention strategies related to obesity?

New research suggests that weight-loss drugs, already bestsellers, may help people avoid obesity-related cancers. Obesity causes 13 types of cancer, and experts are concerned about the rising cancer burden due to globally increasing obesity rates. A new study published in The Lancet eClinicalMedicine indicates that weight-loss medications like Saxenda or Trulicity may reduce this risk.

dailymail.co.uk

🌐 85% Global Worthiness

Feb 24, 04:09

80+ UK Deaths Linked to Weight-Loss Jabs

Over 80 Britons have died, and nearly 400 required hospitalization, after using weight-loss and diabetes jabs like Ozempic and Mounjaro, prompting calls for stricter regulations and raising concerns over the drugs' accessibility.

80+ UK Deaths Linked to Weight-Loss Jabs

Over 80 Britons have died, and nearly 400 required hospitalization, after using weight-loss and diabetes jabs like Ozempic and Mounjaro, prompting calls for stricter regulations and raising concerns over the drugs' accessibility.

Progress

64% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of the reported deaths linked to weight-loss and diabetes medications in the UK?

At least 80 Britons have died after using weight-loss and diabetes medications like Ozempic and Mounjaro, according to a report. The Medicines and Healthcare products Regulatory Agency (MHRA) linked 22 deaths to these drugs by January, with an additional 60 deaths related to Type 2 diabetes treatments. Nearly 400 people also needed hospitalization.

forbes.com

🌐 85% Global Worthiness

Jan 30, 19:11

Ozempic and Surgery: Increased Aspiration Risk

The U.K.'s MHRA warns that weight-loss drugs like Ozempic increase the risk of aspiration (stomach contents entering the lungs) during surgery due to slow gastric emptying, reporting a small number of cases, one resulting in aspiration pneumonia; patients should inform their healthcare providers.

Ozempic and Surgery: Increased Aspiration Risk

The U.K.'s MHRA warns that weight-loss drugs like Ozempic increase the risk of aspiration (stomach contents entering the lungs) during surgery due to slow gastric emptying, reporting a small number of cases, one resulting in aspiration pneumonia; patients should inform their healthcare providers.

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does the mechanism of action of GLP-1 and dual GIP/GLP-1 receptor antagonist drugs contribute to the increased risk of aspiration during surgery?

Weight-loss drugs like Ozempic and Wegovy (containing semaglutide) and Mounjaro (containing tirzepatide) cause slow gastric emptying, increasing the risk of aspiration during surgery. This risk stems from the drugs' mechanism of action which delays the release of food and liquid from the stomach. The MHRA, along with European and U.S. medical authorities, acknowledges this risk, though more research is needed to establish a definitive causal link.

forbes.com

🌐 85% Global Worthiness

Jan 21, 19:10

GLP-1 Drugs Show Unexpected Health Impacts in Large-Scale Study

A study of 215,970 diabetic patients using GLP-1 receptor antagonist drugs found lower risks of 42 conditions (including cardiovascular disease, bacterial infections, and Alzheimer's) and higher risks of 19 (including nausea, low blood pressure, and joint pain) compared to other treatments; further ...

GLP-1 Drugs Show Unexpected Health Impacts in Large-Scale Study

A study of 215,970 diabetic patients using GLP-1 receptor antagonist drugs found lower risks of 42 conditions (including cardiovascular disease, bacterial infections, and Alzheimer's) and higher risks of 19 (including nausea, low blood pressure, and joint pain) compared to other treatments; further ...

Progress

16% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the most significant health benefits and risks observed in the study of GLP-1 receptor antagonist drugs for patients with diabetes, and how do these findings compare to existing knowledge?

A large-scale study of 215,970 patients with diabetes using GLP-1 receptor antagonist drugs revealed a lower risk of 42 conditions, including cardiovascular disease, bacterial infections, psychotic disorders, and Alzheimer's, compared to other treatments. However, increased risks of nausea, vomiting, low blood pressure, and joint pain were also observed.

Showing 1 to 12 of 20 results